Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Related Videos
Che-Kai Tsao, MD
Xingming Zhang, MD
Samer A. Srour, MB ChB, MS
Expert on RCC
Experts on RCC
Brian I. Rini, MD, FASCO
Eric A. Singer, MD
Che-Kai Tsao, MD
Matthew Galsky, MD
Christopher W. Ryan, MD
Related Content